Scholarlink

Background <p>Prostate cancer (PCa) remains the leading cause of cancer deaths in men. The prostate-specific antigen (PSA) test is widely used for PCa screening, but it lacks specificity and can lead to over-diagnosis and over-treatment. New, effective and affordable markers are therefore needed.</p> Results <p>Using enzymatic methyl sequencing (EM-Seq), methylation-specific PCR (MS-PCR), and transcriptomics including a spatial approach, we analyzed tumor and non-tumor samples from radical prostatectomy specimens. Comprehensive methylome was performed in 15 paired samples of prostate cancer and their adjacent non-tumor tissue by EM-Seq. From over 4-million differentially methylated CpG sites, we identified 66 CpGs sites representing eight genes: <i>CLDN5</i>, <i>GSTP1</i>, <i>NBEAL2, PRICKLE2</i>, <i>SALL3</i>, <i>TAMALIN/GRASP</i>, <i>TJP2</i>, and <i>TMEM106A</i> which were hypermethylated in PCa tissues (<i>p</i>-value &lt; 0.0001), and were confirmed by MS-PCR. A very good correlation between EM-Seq and MS-PCR results was observed (Pearson’s correlation of 0.93). Differential expression of these candidate genes was analyzed first, using an Affymetrix RNA array dataset from a cohort of 68 non-tumor samples and 101 tumors with different aggressiveness patterns and, second, by in situ expression using Visium 10X spatial genomics transcriptomics on eight prostate tissue sections with different tumor grades and non-tumor glands. Lower expression level was found, using RNA arrays, in tumor compared to non-tumor tissues for six of the eight genes (<i>p</i> ≤ 0.0001) and in tumor glands with high aggressiveness compared to non-tumor glands (<i>p</i> &lt;  0.0001) for the eight genes using in situ transcriptomics.</p> Conclusions <p>Our study identifies promising DNA methylation markers for the diagnosis of prostate cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multiple highly methylated CpG sites as potential epigenetic markers for the diagnosis of prostate cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月11日

查看全文
  • Jean-Pierre Roperch,
  • Guillaume Charbonnier,
  • Sandy Figiel,
  • Alastair Lamb,
  • Ian Mills,
  • Claude Hennion,
  • Géraldine Cancel-Tassin,
  • Olivier Cussenot

摘要

Background

Prostate cancer (PCa) remains the leading cause of cancer deaths in men. The prostate-specific antigen (PSA) test is widely used for PCa screening, but it lacks specificity and can lead to over-diagnosis and over-treatment. New, effective and affordable markers are therefore needed.

Results

Using enzymatic methyl sequencing (EM-Seq), methylation-specific PCR (MS-PCR), and transcriptomics including a spatial approach, we analyzed tumor and non-tumor samples from radical prostatectomy specimens. Comprehensive methylome was performed in 15 paired samples of prostate cancer and their adjacent non-tumor tissue by EM-Seq. From over 4-million differentially methylated CpG sites, we identified 66 CpGs sites representing eight genes: CLDN5, GSTP1, NBEAL2, PRICKLE2, SALL3, TAMALIN/GRASP, TJP2, and TMEM106A which were hypermethylated in PCa tissues (p-value < 0.0001), and were confirmed by MS-PCR. A very good correlation between EM-Seq and MS-PCR results was observed (Pearson’s correlation of 0.93). Differential expression of these candidate genes was analyzed first, using an Affymetrix RNA array dataset from a cohort of 68 non-tumor samples and 101 tumors with different aggressiveness patterns and, second, by in situ expression using Visium 10X spatial genomics transcriptomics on eight prostate tissue sections with different tumor grades and non-tumor glands. Lower expression level was found, using RNA arrays, in tumor compared to non-tumor tissues for six of the eight genes (p ≤ 0.0001) and in tumor glands with high aggressiveness compared to non-tumor glands (p <  0.0001) for the eight genes using in situ transcriptomics.

Conclusions

Our study identifies promising DNA methylation markers for the diagnosis of prostate cancer.